Nuclear Medicine Imaging For Prediction or Early Assessment of Response to Chemotherapy in Patients Suffering From Breast Carcinoma

[1]  G. D'aiuto,et al.  In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients , 1997, European Journal of Nuclear Medicine.

[2]  J. Kouyoumdjian,et al.  Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression , 1996, European Journal of Nuclear Medicine.

[3]  G. Giaccone,et al.  Molecular Pathways of Drug Resistance , 2004 .

[4]  S. Ho,et al.  P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. , 2001, Cancer research.

[5]  D. Podoloff,et al.  In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. , 2001, Cancer biotherapy & radiopharmaceuticals.

[6]  M. Moore,et al.  In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors. , 2000, Cancer biotherapy & radiopharmaceuticals.

[7]  Jason S. Lewis,et al.  Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET , 2000, European Journal of Nuclear Medicine.

[8]  S. Sun,et al.  Expression of drug resistance protein related to Tc-99m MIBI breast imaging. , 2000, Anticancer research.

[9]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Alavi,et al.  Nuclear imaging methods for non-invasive drug monitoring. , 2000, Advanced drug delivery reviews.

[12]  Manbir Singh,et al.  Physics and instrumentation for imaging in-vivo drug distribution. , 2000, Advanced drug delivery reviews.

[13]  P. Price,et al.  In vivo monitoring of drugs using radiotracer techniques. , 2000, Advanced drug delivery reviews.

[14]  F. Blankenberg,et al.  Apoptotic cell death: its implications for imaging in the next millennium , 2000, European Journal of Nuclear Medicine.

[15]  M. Dowsett,et al.  Apoptosis Pathways: Clinical Relevance , 2000 .

[16]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Dupont,et al.  Early response monitoring with FDG-PET in a phase I study in metastatic breast cancer , 1999 .

[18]  H. Bom,et al.  Double-phase Tc-99m sestamibi scintimammography to assess angiogenesis and P-glycoprotein expression in patients with untreated breast cancer. , 1999, Clinical nuclear medicine.

[19]  M. Moore,et al.  99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. , 1999, Nuclear medicine communications.

[20]  P. Price,et al.  Monitoring Response to Treatment in the Development of Anti-Cancer Drugs Using Positron Emission Tomography (PET) , 1999 .

[21]  N. Davidson,et al.  Apoptosis and Breast Cancer , 1999 .

[22]  L. Kostakoglu,et al.  Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R. Thomas,et al.  Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Davies Cl.  Multidrug resistance in bladder and breast cancer. , 1998 .

[25]  M. Marmion,et al.  Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  N. Tamaki,et al.  Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  B. Trock,et al.  Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. , 1997, Journal of the National Cancer Institute.

[28]  New Opportunities in Molecular Imaging Using Pet , 1997 .

[29]  L. Kostakoglu,et al.  Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  J. Pruim,et al.  Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  R L Wahl,et al.  Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  David J. Yang,et al.  Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  J. Kouyoumdjian,et al.  Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  J. Bergh,et al.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Ballinger,et al.  99Tcm‐sestamibi as an agent for imaging P‐glycoprotein-mediated multi‐drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxirubicin‐resistant variant , 1995, Nuclear medicine communications.

[36]  M. Senda,et al.  A comparative study on protein incorporation of L-[methyl-3H]methionine, L-[1-14C]leucine and L-2-[18F]fluorotyrosine in tumor bearing mice. , 1993, Nuclear medicine and biology.

[37]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Någren,et al.  Expert Testimony versus Junk Science , 1993, Environmental Health Perspectives.

[39]  K. Någren,et al.  Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. , 1993, British Journal of Cancer.

[40]  R L Wahl,et al.  Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  R. Kramer,et al.  Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. , 1993, Cancer research.

[42]  Y. Magata,et al.  Evaluation of experimental liver tumors using fluorine-18-2-fluoro-2-deoxy-D-glucose PET. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  J. Itami,et al.  Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  R. Kronmal,et al.  A southwest oncology group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer , 1991 .

[45]  K. Ishiwata,et al.  A comparative PET study using different 11C-labelled amino acids in Walker 256 carcinosarcoma-bearing rats. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[46]  D. Kern,et al.  Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. , 1990, Journal of the National Cancer Institute.

[47]  D. D. Hoff,et al.  He's not going to talk about in vitro predictive assays again, is he? , 1990, Journal of the National Cancer Institute.

[48]  S. Steinberg,et al.  Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. , 1990, Journal of the National Cancer Institute.

[49]  D. V. Von Hoff.  He's not going to talk about in vitro predictive assays again, is he? , 1990, Journal of the National Cancer Institute.

[50]  K. Storch,et al.  Quantitative study in vivo of methionine cycle in humans using [methyl-2H3]- and [1-13C]methionine. , 1988, The American journal of physiology.

[51]  Heikki Joensuu,et al.  Florodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors , 1988 .

[52]  H. Minn,et al.  Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. , 1988, Cancer.

[53]  J. Mazziotta,et al.  Criteria for the tracer kinetic measurement of cerebral protein synthesis in humans with positron emission tomography , 1984, Annals of neurology.

[54]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. , 1978, European journal of cancer.

[55]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[56]  川島 吉良.  絨毛性腫瘍のPrimary chemotherapy(カラー・ページ) , 1974 .